MAPT Antibody - middle region: FITC (ARP48103_P050-FITC)

MAPT is differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. The mutations in the gene have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.

Ywhaz; Prkaca; STUB1; PHGK; SRC; PRKAR1A; GSK3B; FYN; DCTN1; CSNK1A1; CDK2; AKT1; ABL1; YWHAQ; SGK1; MARK2; MARCH7; TUBB3; TUBA1B; UBC; TUBA4A; MARK4; PEG10; MARK3; MARK1; MAPK13; MAPK11; MAPK8; mapk14; Mapk12; LIMS1; HSPA1A; PPP5C; PPP2R4; CAPN2; PKN1; H

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.